RET in thyroid cancer
3 EU-approved indications in thyroid cancer need a RET result: vandetanib (advanced), selpercatinib (advanced) and selpercatinib (advanced).
Histology
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| RET3 | ||||
Retsevmo | Monotherapy | Any line advanced | Radioactive iodine-refractory (if radioactive iodine is appropriate); aged 2 years and older | |
Retsevmo | Monotherapy | Any line advanced | Medullary thyroid cancer only; Aged 2 years and older | |
Caprelsa | Monotherapy | Any line advanced | Medullary thyroid cancer only; Aggressive and symptomatic disease; aged 5 years and older | |
Tumour-agnostic approvals1
Approved for any solid tumour that carries the alteration, wherever the tumour started.
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| RET fusion1 | ||||
Retsevmo | Monotherapy | Any line advanced | Treatment options not targeting RET provide limited clinical benefit, or have been exhausted; Aged 2 years and older | |
4 approvals for Thyroid need no biomarker and apply whatever the result. All approvals for Thyroid
See also
Label wording3
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Vandetanib (Caprelsa)
Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
- Selpercatinib (Retsevmo)
advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- Selpercatinib (Retsevmo)
advanced RET-mutant medullary thyroid cancer (MTC).